Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.51 |
| ▸ | JAK1 | P23458 | 19/20 | 0.51 |
| ▸ | JAK3 | P52333 | 17/20 | 0.51 |
| ▸ | TYK2 | P29597 | 16/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800235 | 0.92 | JAK2 (0.49) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2796117 | 0.89 | JAK2 (0.67) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL2799758 | 0.87 | JAK2 (0.47) | JAK2JAK1JAK3TYK2GAK | |
| SCHEMBL2801044 | 0.84 | JAK2 (0.47) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2799458 | 0.83 | JAK2 (0.41) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL2800095 | 0.81 | JAK2 (0.64) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL2801004 | 0.79 | JAK2 (0.69) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL2799636 | 0.79 | JAK2 (0.78) | JAK2JAK1JAK3TYK2ABL1 | |
| SCHEMBL2798305 | 0.78 | JAK2 (0.62) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2802198 | 0.78 | JAK2 (0.44) | JAK2JAK1JAK3TYK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | claimed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | claimed |
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.